41 results about "Neo adjuvant chemotherapy" patented technology

The present invention relates to methods of predicting the probability of pathological complete response (pCR) of a breast cancer patient upon neo-adjuvant chemotherapy, to methods for selecting a breast cancer treatment, to methods of treatment of breast cancer, and to methods of prognosis of breast cancer upon breast cancer treatment.

The present invention provides methods for individualizing chemotherapy, and particularly methods for individualizing neoadjuvant chemotherapy. The present invention provides methods for predicting a cancer patient's response to neoadjuvant chemotherapy, including assessing the probability of a positive response upon treatment with candidate agents prior to surgery. In various aspects, the invention involves culturing a monolayer of malignant cells from an explant of a patient's biopsy specimen, such as a transcutaneous biopsy-sized specimen, and testing the malignant cells for resistance or sensitivity to one or a plurality of candidate agents for neoadjuvant therapy. In other aspects, the invention provides methods for accurately scoring and interpreting such assays, and discloses in vitro chemoresponse results that are predictive of a patient's pathological complete response (pCR) upon receiving the corresponding treatment regimen.

The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at two or more of chromosome 5p15, 7p12, 8q24 and centromere 6 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. Assessment of the copy number abnormality patterns using four classifiers produced statistically significant prognostic classification for NSCLC: (i) the Range3 pattern of cells showing a difference on a cell by cell basis, of at least three FISH probe signals between the FISH signals at the chromosomal locus with the largest number of FISH signals minus the FISH signals at the chromosomal locus with the lowest number of FISH signals; (ii) the MYC / EGFR % loss pattern assessing the percentage of cells showing fewer MYC FISH probe signals than EGFR FISH probe signals; (iii) a combination of the Range3 pattern and the MYC / CEP6 ratio pattern of a percentage of cells showing a relative loss of MYC FISH probe signals to the FISH probe signal for CEP6; (iv) the combination of the MYC / 5p15 ratio pattern showing the relative ratio of MYC and 5p15 locus signals of ≧0.80 and the 5p15 / CEP6 ratio pattern assessing percentage of cells having a relative ratio of 5p15 FISH probe signals to CEP6 FISH probe signals ≧1.1 versus MYC / 5p15 ratio of <0.80 or 5p15 / CEP6<1.1; and (v) a combination of the average range of probe signal differences of equal to or greater than about 2.5 with the Range3 pattern in a percentage of the cells. The invention can be used to identify those early stage NSCLC patients at higher risk of recurrence who should be treated with neoadjuvant chemotherapy before surgery or with adjuvant chemotherapy after surgery.

The present invention relates to methods for predicting the efficacy of anthracycline-based neo-adjuvant chemotherapy in triple-negative breast cancer. This is achieved by determining epigenetic changes within the PITX2 gene. Detection of the methylation state of Cp G sites in a genomic sequence of PITX2 allows an estimate of the response or failure of an individual breast cancer patient to neo-adjuvant therapy.

The present invention provides a circular RNA for predicting the sensitivity of triple negative breast cancer to neoadjuvant chemotherapy. The circular RNA is hsa_circRNA_038632, and its nucleotide sequence is shown in SEQ ID NO: 1. The invention also provides a kit for predicting the sensitivity of triple negative breast cancer neoadjuvant chemotherapy. The present invention discovers for the first time the correlation between hsa_circRNA_038632 and the responsiveness of triple-negative breast cancer patients to neoadjuvant chemotherapy. By detecting the expression level of hsa_circRNA_038632, the responsiveness of triple-negative breast cancer patients to neoadjuvant chemotherapy can be predicted, thereby helping Doctors determine chemotherapy regimens for patients with triple-negative breast cancer.

The invention provides the use of the PDL1 SNP genotype in the preparation of markers for diagnosis and prediction of the curative effect of neoadjuvant chemotherapy for breast cancer. Also provided is the use of the PDL1 SNP genotype as a marker in the preparation of reagents for diagnosing and predicting the curative effect of neoadjuvant chemotherapy for breast cancer. Also provided is a kit for detecting the PDL1 SNP genotype, which contains the primers shown in SEQ ID NO.1-18. The present invention finds that in all breast cancer populations and HR-positive populations, after the SNP rs4143815 C to G change in the non-coding region of PDL1 gene, patients with GC genotype are more likely to achieve pCR than patients with GG and CC genotypes. Through the detection of the SNP in the non-coding region of the PDL1 gene in the patient's blood, patients with the GC genotype can be detected as early as possible, and neoadjuvant chemotherapy can be performed in order to achieve complete remission of the pathology and improve the survival time.